“Other Support” is sometimes referred to as “current and pending support” or “active and pending support.” The instructions, blank format pages, and sample Other Support documents can be found here.

NIH requires the submission of a biosketch for each proposed senior/key personnel and other significant contributor on a grant application. Some funding opportunities or programs may also request biosketches for additional personnel (such as the Participating Faculty Biosketch attachment for institutional training awards).

An update on the guidance issued in NOT-OD-25-110 is provided by this notice. The No-Cost Extension functionality within eRA Commons has been re-enabled by NIH after issuing this Guide Notice. Recipients may resume initiating the first no-cost extensions in eRA Commons, in accordance with the NIH Grants Policy Statement, Section 8.1.1.3. Requests that were previously submitted via the prior approval module will not be reviewed, and recipients will need to initiate the first no-cost extension within the Status module by using the Extension action.

As previously announced, effective with the August/October Council round, all NIH peer review of contracts, grants, and cooperative agreements is centralized within the Center for Scientific Review. Updated peer review contact information will be listed in eRA Commons typically two weeks after the due date.

As previously noted in NOT-OD-25-104, NIH must ensure that it can report transparently and reliably on each dollar spent on foreign collaborations. The current subaward structure does not allow for consistent reporting and accurate tracking. Therefore, NIH will not issue awards to domestic or foreign entities (new, renewal, or non-competing continuation) that include a subaward to a foreign entity. This Guide Notice updates the policy concerning existing projects and submitted applications.

The purpose of this notice is to remind users of NIH's Electronic Research Administration (eRA) systems of the longstanding security requirements. NIH regularly audits its system access and credential use logs to assess compliance and risk as part of their security posture.

NIH is proposing that this Policy cover all direct publication costs, including APCs and other publishing fees, for grants, contracts, and other transactions. Any publication costs would only be allowed for accepted articles, as noted in NIH's Publication Cost Guidance, which outlines other applicable cost considerations. 

All new and competing awards and proposals for contracts submitted to NIH for receipt dates on or after January 1, 2026, or Other Transactions executed on or after January 1, 2026, will be expected to comply with this policy.

All other awards, contracts, and other transactions active on or after January 1, 2026, are expected to comply with this policy by the start of the first budget period or the start of the first reporting period following January 1, 2026.

NIH is providing guidance to researchers on the appropriate usage of artificial intelligence (AI) to maintain the fairness and originality of NIH’s research application process. NIH is also instituting a new policy limiting the number of applications that NIH will consider per Principal Investigator per calendar year.

Effective October 1, 2025, recipients must implement trainings, in addition to maintaining a written and enforced policy, on requirements for the disclosure of other support to ensure Senior/Key Personnel fully understand their responsibility to disclose all resources made available to the researcher in support of and/or related to all of their research endeavors, regardless of whether or not they have monetary value and regardless of whether they are based at the institution the researcher identifies for the current grant.

This notice informs the extramural community that beginning in fiscal year 2026, NIH will no longer post NOFOs in the NIH Guide. The only official source for funding opportunities for grants and cooperative agreements will be Grants.gov. The NIH Guide will continue to be used for policy and informational notices.

Part of the High-Risk, High-Reward Research program, the award supports scientists with outstanding records of creativity who are pursuing new research directions to develop pioneering approaches to major challenges in biomedical, social science, and behavioral research.

•   Open to all career stages
•   Single PI only
•   No preliminary data required
•   Must be a new scientific research direction
•   Minimum of 51% research effort in the first 3 years
•   3 Letters of Reference required
•   $700,000 in direct costs per year for up to 5 years

RFA-RM-25-001

Applications due September 9, 2025

The NIH Extramural Loan Repayment Program (LRP) application cycle is open from September 1 to November 20 this year. The amount awarded is equal to one-quarter of the total eligible debt, up to $50,000, for each year of the award. To receive the maximum amount of $100,000 for a two-year award, you must have at least $200,000 in eligible educational debt at the contract start date.

Please contact lrp@nih.gov for further details. 

Extramural LRP applicants are strongly encouraged to review the Extramural LRP Application Instruction Guide in its entirety prior to starting an application. Doing so will greatly streamline the application process and allow applicants to make a timely submission.

NIH fellowships are open to early career scientists, including those at the predoctoral and postdoctoral levels and are designed to provide mentored research training to enable skill development and experience needed to transition into careers in the biomedical research workforce.

This is to notify the research community of the approaching FY25 pre-application deadlines for the Department of Defense (DOD) Melanoma Research Program (MRP) managed by the Congressionally Directed Medical Research Programs (CDMRP).

Letter of Intent (LOI) due September 10^th; NO Invitation to Submit Full Application:

·       Melanoma Academy Scholar Award ($770,000 total costs)

·       Melanoma Academy Leadership Award ($1,820,000 total costs)

·       Survivorship Research Award ($1,015,000 total costs)

**Be sure to view the newly posted FY25 MRP Funding Overview webinar and FY25 MRP Funding Opportunity FAQ now available on the MRP webpage, https://cdmrp.health.mil/mrp/default.**

Reminders:

·       All FY25 MRP cost caps are now TOTAL COST caps (direct + indirect costs).

·       All FY25 MRP awards recommended for funding will be fully funded, up front with FY25 funds and have periods of performance that begin no later than 30 September 2026. The availability of future fiscal year appropriations will not impact funding levels of FY25 awards.

Click here to view the funding opportunities for the FY25 Melanoma Research Program (MRP).

To view the program announcements and submit a pre-application visit: 

 https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103

The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) have joined forces to invest $5 to 7 million over approximately five (5) years in hairy cell leukemia (“HCL”) research, including the HCLF Patient Data Registry. The Parties wish to collaborate to invest a portion of these funds in targeted research to uncover novel features of classic HCL biology, understand the distinguishing features of HCL variant (“HCLv”) and apply that knowledge in the clinic, translate new medical knowledge to clinical application, test novel treatments in patients through clinical trials, and apply the HCL registry created by HCLF to examine long-term outcomes and quality of life. This initiative is called The Hairy Cell Leukemia Foundation-Leukemia & Lymphoma Society HCL2030 Initiative (HCL2030).

The goals of the HCL2030 grant program are focused on four major efforts:

I. Uncovering novel features of cHCL biology

II. Understanding the distinguishing features of HCLv and applying that knowledge in the clinic

III. Translating new medical knowledge to clinical application and testing novel treatments in patients through clinical trials

IV. Applying the HCL registry created by HCLF (Andritsoes et al, 2023) to examine long-term outcomes and quality of life

These activities should be driven ultimately by the overarching goal to improve patient outcomes and cure the disease. 

There are two funding mechanisms under HCL2030 as follows:

Laboratory to Clinical Research Grants (LCRGs)

• Projects focused on translational research, including basic research if justified, that has relevance to therapeutic development
• Project led by a single Principal Investigator (PI) but may have one co-PI
• 3 years of support, with the third-year funding dependent on progress assessment at the end of year 2
• Cost not to exceed $250,000/yr ($750,000 total), including direct costs
• Indirect costs (institutional overhead) capped at 10% of the total grant award; our goal is to maximize funds directed to actual research
• Funds intended for flexible use may include salaries (capped at 40%), equipment, supplies, or personnel. 
• A Patient Involvement Plan (PIP) is required for LCRGs if a clinical trial is involved

Collaborative Team Grants (CTGs)

• Projects focused on the development and implementation of novel clinical trials that are feasible within the time period of the grant
• Program activities can include pre-clinical development and correlative studies
• Either one trial with supporting correlative work or multiple projects with related but distinct approaches that contribute to a transformational advance in the treatment of HCL
• Up to 4 investigators (Project Leaders) led by a Program Director (PD)
• Funding for core facilities (e.g., chemistry, genomics, animal models, computation) may be included but cannot exceed 20% of the total cost
• Up to 4 years of support
• Cost not to exceed $625,000/yr ($2,500,000 total), including indirect costs; more focused applications may not require the maximum amount of funding
• Indirect costs (institutional overhead) capped at 10% of the total grant award; our goal is to maximize funds directed to actual research
• Funds intended for flexible use may include salaries (capped at 40%), equipment, supplies, or personnel
• Demonstration of other financial support for the proposed work from industry or other NFPs, which leverages funding provided by HCLF and LLS is encouraged
• A Patient Involvement Plan (PIP) is required for CTG grants

A detailed description of the LLS Hairy Cell Leukemia (HCL2030) Program and application instructions are available on the LLS Research Portal or https://www.lls.org/research/apply-hairy-cell-leukemia. All applications are to be submitted online through the LLS Research Portal. 

For additional questions regarding LLS research grant programs, eligibilty, and application processes, please contact researchprograms@lls.org.

·      Due: September 9, 2025

·      Amount: $150,000-240,000 over 2-3 years

To support “patient-oriented research conducted with human participants, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research.”  These early-career clinical research awards are available in ALS, Myasthenia Gravis, Lewy Body Diseases ($150K), Alzheimers and Dementia, PI must have completed residency or a PhD no more than 7 years prior to the beginning of this award (July 1, 2026).  

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

·      Due: September 9, 2025

·      Amount: $150,000 over 2 years

To fund “patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease.” Research award programs are available for dementia/Alzheimer’s, Stroke, ALS, MS, FTD, Parkinson’s, Central Vestibular Neurological Disorders, Peripheral Neuropathy, Epilepsy, and Neuroscience Preclinical Research. See website for each award’s detailed RFA. PI must have completed clinical residency or PhD no more than 5 years prior to the beginning of this award (July 1, 2026).

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

·      Due: September 9, 2025

·      Amount: $150,000 over 2 years

For the purpose of this scholarship, research is defined as “patient-oriented research conducted with human subjects, or translational research specifically designed to develop treatments or enhance diagnosis of neurological disease. These areas of research include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research.” PI must have completed clinical residency or PhD no more than 5 years prior to the beginning of this award (July 1, 2026).  

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The Leukemia & Lymphoma Society (LLS) has released a Request for Proposals (RFP) for its Equity in Access Research Program, which is dedicated to funding health services research.

The LLS is reissuing the RFP Building Evidence for Effective Interventions to Increase Therapeutic Cancer Clinical Trial Accrual: Promoting Access for Patients from Underrepresented Groups. Awards will be a maximum of $2.5 million each over 5 years.

Specifically, the LLS seeks proposals that will implement and evaluate interventions designed to:

·        Mitigate multilevel barriers to therapeutic clinical trial accrual for underrepresented groups

·        Quantitatively measure the impact of these interventions on patient accrual

The LLS is particularly interested in proposals that address systemic, institutional, and/or clinician-related barriers that impede clinical trial participation.

It is not necessary for applicants to have previously conducted research in blood cancer. The due date for Letters of Intent is September 11, 2025, at 3 pm ET. 



The RFP and additional information are available at LLS.org/EquityinAccess.

Postdoctoral and Clinical Research Fellow Grant: Up to $100,000 over 2 years

Independent Investigator Grant: Up to $100,000 over 2 years

Outside the Box Grant: $50,000 over 1 year, with possibility to renew

20/20 Alumni Visionary Grant: Up to $200,000 over 2 years

·      Due: September 12, 2025 (LOI)

Funding is available for pediatric cancer research that leads to advanced studies or clinical trials, and for basic science with strong translational potential. Other areas of interest include personalized, targeted, or integrative research proposals, under-studied cancer types, and quality of life, survivorship and palliative care studies.



·      Eligibility: Applicants who are postdoctoral or clinical research fellows, all academic ranks, Instructor to Professor, and research scientists with M.D., D.O., Pharm.D. and/or Ph.D. degrees. For the 20/20 Alumni Visionary Grant, PI must have previously been awarded funding from Rally.

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

·      Due: September 30, 2025

·      Amount: individual projects $150,000/1 year; multi-PI projects $300,000/1 year

The foundation is looking for innovative ideas that can lead to improvements in prevent, predicting, diagnosing, and treating IBD. The foundation encourages high-impact basic and translational research that uses AI and ML, big data analytics and various model systems to deepen our understanding of IBD mechanisms. Collaborative projects are highly encouraged.

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The Brain Health Medicine Scholars selection committee is seeking:

• Discoveries demonstrating rigorous science, creativity, innovation, and potential for clinical impact 
• Any therapeutic modality
• Novel, validated targets  

The Brain Health Medicines Scholar Award provides funding and drug development support to researchers whose work aims to treat, prevent, or cure Alzheimer's disease and related dementias. The award includes:

• One-year grant
• $100,000 with appropriate justification 
• Potential to renew for a second year based on milestones achieved 
• Dedicated Project Manager for the duration of the award
• Drug development, commercial strategy and business development support from Harrington's Therapeutics Development Center experts
• Opportunity to quality for up to $400,000 in additional funding and drug development support 

Eligibility Criteria

• MD or PhD (or equivalent)
• Faculty position at an accredited academic medical center, university or research institution in the US, Canada, or UK, and conduct the majority of their research at that institution
• A project must have a single Principal Investigator (PI) who will be named the Scholar and who is responsible for project oversight and financial management. The PI may engage collaborators, core labs or commercial CROs to execute any portion of the project.
• Past recipients of Harrington awards may submit new and distinct proposals, but may not seek additional support for previously funded projects.

This call is currently open for submissions. Applications may be submitted at any time and will be reviewed quarterly. Deadlines to submit an application for review are March 31, June 30, September 30, and December 31 each year. Applicants will be notified of the results of the application review prior to the next submission deadline.

·      Due: September 29, 2025 (LOI)

·      Amount: $750,000

Supports and empowers early-to-midcareer investigators to rethink conventional paradigms around neurodegenerative diseases. Projects may range from the invention of novel tools, techniques, and technologies for mapping and analyzing the brain to bold approaches that demonstrate extraordinary therapeutic potential. Research domains may include—but are not limited to—neurobiology, brain imaging and mapping, machine learning, drug delivery, and synthetic biology. The foundation seeks high-risk, high-reward proposals that focus on novel interdisciplinary approaches to neuroscience research and are grounded in sound reasoning from first principles. The MIND Prize was created to fund projects that have been deemed too risky or speculative for traditional funding sources but still hold the potential for radical impact. Proposals that articulate a clear application to neurodegenerative and neurocognitive disorders, with a lens of Alzheimer’s Disease and Dementias, will be favored.

·      Eligibility: An MD, PhD, or MD-PhD (or equivalent) is required. Applicants must have completed at least one (1) but no more than ten years of independent research experience as a tenure-track faculty member by the start date of the Prize (May 2025). An applicant, who is not a U.S. citizen or permanent resident, by submitting an application for this funding, assures that his/her visa status will provide sufficient time to complete the project and grant term within the United States. Investigators need not be specifically trained in neuroscience.

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

·      Due: September 29, 2025

·      Amount: $200,000-$300,000 over 2-3 years

Grants will be awarded to scientists pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer’s disease.  Standard Awards of $300,000 are available for early investigators, “who have obtained their MD, PhD, or equivalent degree and/or completed formal medical training/residency within the past 12 years at the time of application.” Postdoctoral Awards of $200,000 are available for researchers in the final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant’s independent research career.



Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

·      Due: October 15, 2025

·      Amount: $250,000 over 2 years

Innovation Grants provide seed funding to experienced investigators with hypothesis-driven research to develop novel and promising ideas. Proposals may represent a change in research direction and/or an innovative idea that moves away from an investigator’s prior research. Successful applications will clearly demonstrate innovation as well as the impact the project will have for children with cancer. The potential for major scientific and/or clinical impact in pediatric oncology is critical. Applicants for this award should have a strong track record of research, with at least one published first-author paper.  While preliminary data are not required, the applicant must demonstrate feasibility of the research plan.



Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The Leukemia & Lymphoma Society’s Career Development Program (CDP) supports scientists studying basic, translational, or clinical research to help understand and treat hematologic malignancies and relevant premalignant conditions.

The program welcomes applications worldwide from appropriate non-profit academic institutions and investigators of any nationality. Non-citizens and non-residents are eligible. You do not need a green card to apply or hold the CDP award.

Application Deadlines

Eligibility Phase Deadline October 17, 2025; 3:00 PM (ET)

Letter of Intent Phase Deadline November 1, 2025, 3:00 PM (ET)

Blind Letters of Reference Deadline:November 15, 2025, 3:00 PM (ET)

Full Application Phase Deadline November 15, 2025, 3:00 PM (ET)

Award Start Date July 1, 2026

Research Subject Matter 

CDP applicants must have a research focus on hematological malignancies and relevant premalignant conditions. We are interested in all research studies on any of these subjects. The research may have a basic mechanistic focus to better understand these diseases or may be preclinical/clinical studies using any approach with the goal of achieving better therapeutic outcomes. 

Award Categories:

Scholar. These 5-year, $120,000/year awards support emerging leaders in the blood cancer research field. You must be a highly qualified, early/mid-career laboratory-based investigator who has an impactful and innovative research program focused on hematologic malignancies and/or relevant premalignant conditions. You must hold an independent, tenure-track, faculty-level position and should have substantial research support from a national agency.

Scholar in Clinical Research. These 5-year, $125,000/year awards support highly qualified clinical investigators who hold an independent faculty-level appointment and are conducting independent applied research that will advance the prevention, diagnosis, and/or treatment of hematologic malignancies and/or relevant premalignant conditions. The research must involve patients and be related to your overall clinical activities. You must have substantial support for your research from another source.

Special Fellow. These 2 or 3 year, $75,000/year awards support highly qualified, mentored postdoctoral fellows and instructors who have 3-5 years of postdoctoral research training (as of the award start date) and are continuing a research program of direct relevance to hematological malignancies and/or relevant premalignant conditions. In addition, your Sponsor must have the appropriate experience to mentor you as you engage in blood cancer research. This award provides you with the opportunity to continue building a research program that will make you competitive for an independent position by the end of the award funding period.

Fellow. These 3-year, $70,000/year awards support top performing, mentored postdoctoral fellows and instructors who are training for a career in hematological malignancy research and/or treatment and who have up to 3 years of postdoctoral research training (as of the award start date). Your Sponsor must have the appropriate experience to mentor you as you engage in blood cancer research.

Application Process:

The application process has three phases. The first phase is submission and consideration of eligibility. All eligible applicants will be invited to proceed to the Letter of Intent and Full Application phases. All submissions must be made through the LLS Research Portal.

Please visit our website, https://www.lls.org/research/apply-career-development-program-cdp for how to apply. Detailed instructions for each award category are found in the CDP Guidelines and Instructions.

For questions, please contact researchprograms@lls.org.

Albert Einstein College of Medicine would like to submit one candidate’s application for consideration for the Warren Alpert Distinguished Scholar Fellowship Award, which supports individual postdoctoral scientists of exceptional creativity in the field of neurosciences. These transition awards are intended to enable a postdoctoral researcher to advance to become a full-time faculty member at the Assistant Professor or higher level, and to promote the development of a laboratory program that will lead to independent funding. The institution appointing the scholar will be awarded $200,000 annually for two years to cover salary, lab costs, and related expenses. Under certain circumstances, the awardee may transfer funding to support their beginning faculty position. Indirect costs of up to 15% of direct costs may be included in the $200,000.

Eligibility requirements:

• Must have an MD, PhD, or both
• Must hold a postdoctoral research position
• Minimum of 3 years and no more than 6 years of a postdoctoral fellowship by July 1, 2026
• Research focused in the field of Neuroscience
• Must be nominated by the dean of the medical school or equivalent institutional senior leader
• Must include a nomination letter
• Commitment of a minimum of 75% effort
• Three letters of recommendation
• Budgets submitted in G300 format
• Applicants with a Visa are allowed to be nominated with the stipulation that their Visa status must allow them to complete the award here in the United States

To implement the application process for this competition, eligible postdocs are invited to submit preliminary applications, for review by the Awards Committee. From among these applications, the Committee will make recommendations and will select one candidate, who will be invited to submit the full proposal electronically no later than November 1, 2025, to the Warren Alpert Foundation by 5:00 pm. The application link along with submission instructions can be found here.

The deadline for submission of preliminary applications for internal review by the Awards Committee is Friday 5 pm, September 26th, 2025. 

For internal review of your application by the Awards Committee, please send a single (ONE) PDF file containing the following as an email attachment to indranil.basu@einsteinmed.edu: 

1. A written proposal containing a title, a project summary (250-word limit), Introduction, importance of the project, methods and likely presentation results (No more than 4 pages – use 1/2" margins and Arial 11-point font. The 4 pages must include all text and figures and not references).
2. Biosketch (Submit in NIH format - Limit to no more than 5 pages)
3. Bibliography.



The Warren Alpert Scholars Program accepts nominated applications only through their online application system. Once our Awards Committee selects the nominee, we will assist the nominated candidate to submit the final application to the Foundation. 

If you have any questions concerning this award or the application procedure, please contact indranil.basu@einsteinmed.edu.